DR. HINRICH STAECKER MD, PhD

University of Kansas Medical Center
3901 Rainbow Boulevard, MS 3010
Kansas City, KS 66160

 

BIOGRAPHY

Staecker is the Principal Investigator for the first gene therapy trial (CGF166) to restore hearing in patients with severe-to-profound hearing loss.  Dr. Staecker’s clinical practice is focused on Neurotology, and Otology. Dr. Staecker is also the Principal Investigator for the Kansas City investigative site for a Phase 2b Study of SPI-1005 to reduce the Incidence, Severity, and Duration of Acute Noise Induced Hearing Loss (NIHL).  Dr. Staecker’s research focuses on developing treatments for hearing loss. Currently, the main effort of his research lab is focused on developing gene therapy for the treatment of an inner ear disease. Dr. Staecker is also involved in clinical studies on cochlear implants and a totally implanted hearing aid.  Dr. Staecker has published numerous articles and book chapters and is the Director Division of Otology/Neurotology-Dept of Otolaryngology- Head and Neck Surgery; Tenured Professor, Dept of Otolaryngology- Head and Neck Surgery; Tenured Professor, Dept of Hearing and Speech; Tenured Professor, Dept of Neurosurgery.

 

CLINICAL AREAS

Dr. Staecker’s clinical practice is focused on Neurotology, and Otology. Dr. Staecker’s specialties include Skull Base Surgery, ENT-Otology, Hearing and Speech, Neurotology, and Open Skull Base Surgery.  Dr. Staecker has been in practice for over 24 years. 

CURRENT CLINICAL TRIAL ACTIVITY

TITLE: A Three-part, Multicenter, Open Label, Single Dose Study to Assess the Safety, Tolerability, and Efficacy of Intra Labyrinthine (IL) CGF166 in Patients With Severe-to-profound Hearing Loss.  Identifier: NCT02132130, Sponsor: Novartis

ROLE: Dr. Staecker is the Principal Investigator for the Kansas City investigative site.

DESCRIPTION: A phase 1 and 2 Study of the Gene Therapy CGF166 in Patients with Severe-to-Profound Hearing Loss.  A three-part, multicenter, open label, single dose study of the gene therapy CGF166 in patients with severe-to-profound hearing loss. 

CGF166 is recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA. The purpose of the study is to evaluate the safety, tolerability, and the potential ability of CGF166 delivered through intra-labyrinthine infusion to improve hearing and vestibular function.


TITLE: A Phase 2b Study of SPI-1005 to Reduce the Incidence, Severity, and Duration of Acute Noise Induced Hearing Loss (NIHL) Identifier: NCT02779192, Sponsor: Sound Pharmaceuticals

ROLE: Dr. Staecker is the Principal Investigator for the Kansas City investigative site.

DESCRIPTION: A Phase 2b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of SPI-1005 to Reduce the Incidence, Severity and Duration of Acute Noise Induced Hearing Loss (NIHL).  Recruitment to begin in Sept 2016.

SPI-1005 is a novel oral drug that contains a glutathione peroxidase mimetic (ebselen) that will be tested in subjects with a history of NIHL at risk for additional NIHL. The goal of this multi-center Phase 2b study is to determine whether SPI-1005 is effective in reducing an acute NIHL in this affected population. In this Phase 2b study subjects with prior NIHL will be enrolled and exposed to a calibrated sound challenge (CSC) that induces a slight acute NIHL.

RESEARCH INTERESTS

Dr. Staecker’s research focuses on developing treatments for hearing loss. Currently, the main effort of his research lab is focused on developing gene therapy for the treatment of an inner ear disease. Dr. Staecker is also involved in clinical studies on cochlear implants and a totally implanted hearing aid. Dr. Staecker has published numerous articles and book chapters.

BOARD CERTIFICATIONS

Dual board certified in Otolaryngology and Neurotology by the American Board of Otolaryngology

National Board of Medical Examiners

EDUCATION AND TRAINING

  • Medical School: Albert Einstein College of Medicine, New York, NY with distinction in Otology Research.

  • PhD: University of Liege, Liege Belgium, Summa cum laude

  • Internship: Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY – General Surgery

  • Fellowship: Albert Einstein College of Medicine, New York, NY – Neuropathology

  • Residency: Montefiore Medical Center – Otolaryngology

  • Fellowship: Harvard Medical School/Massachusetts Eye and Ear Infirmary, Boston, MA – Otology/Neurotology

COMMITTEES / SOCIETIES / MEMBERSHIPS

  • American Academy of Otolaryngology – Head and Neck Surgery (Fellow)

  • American Neurotological Society

  • Association for Research in Otolaryngology

  • Society for Inner Ear Biology

  • Smith Intellectual and Developmental Disabilities Research Center

  • Kansas City Super Doctors

  • American Otological Society

  • Collegium Oto-Rhino-Laryngologica

  • Triological Society (Fellow)

HONORS AND AWARDS

  • 1987 – Delta Phi Alpha Honors Society

  • 1991 – Alpha Omega Alpha

  • 1993-97 – Resident Travel Award, Association for Research in Otolaryngology

  • 1997 – Winner Resident Research Prize, New York Academy of Medicine

  • 1997 – Second Prize Otolaryngology Head and Neck Surgery Resident Research Competition (Clinical)

  • 2004 – American Academy of Otolaryngology- Head and Neck Surgery Honor Award

  • 2008 – Resident Teaching Award, Otolaryngology- Head and Neck Surgery Department, University of Kansas Medical Center

  • 2008 – David S. and Marilyn M. Zamierowski Professorship in Skull Base Oncology, University of Kansas School of Medicine

  • 2009 – Inducted into Hear-Ring-International cochlear implant research society. One of 2 U.S. members

  • 2013 – Fowler Thesis Awardee, Triological Society. ENT National Academic Society, Elected to Collegium Oto Rhino Larynogologicum International Otolaryngology Honors Society, www.corlas.org

SIGN UP FOR OUR NEWSLETTER